Fimaporfin - PCI Biotech

Drug Profile

Fimaporfin - PCI Biotech

Alternative Names: Amphinex; PC-A11; PC-A22; TPCS-2A

Latest Information Update: 01 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PCI Biotech
  • Developer Norwegian Radium Hospital; PCI Biotech; University Hospital Zurich
  • Class Antineoplastics; Benzenesulfonates; Porphyrins; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I/II Cholangiocarcinoma
  • Preclinical Malignant melanoma
  • Discontinued Bladder cancer; Head and neck cancer

Most Recent Events

  • 30 Aug 2018 PCI Biotech plans a fimaChem pivotal trial in Cholangiocarcinoma (Inoperable\Unresectable, First line therapy, Combination therapy) by early 2019
  • 30 May 2018 Fimaporfin - PCI Biotech receives Orphan Drug status for Cholangiocarcinoma in European Union, prior to May 2018 (PCI Biotech website, May 2018)
  • 04 Oct 2017 Fimaporfin receives Orphan Drug status for Cholangiocarcinoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top